Perspective Therapeutics advances radiopharmaceutical pipeline with lead 212Pb programs.

Perspective Therapeutics presented clinical data on three wholly-owned radiopharmaceutical candidates targeting oncology indications including neuroendocrine tumors, melanoma, and solid tumors. The company's next-generation alpha-emitter platform and regional manufacturing strategy position it to expand the addressable market for targeted cancer therapies.